Gain Therapeutics’ (GANX) Buy Rating Reaffirmed at Roth Mkm

Roth Mkm restated their buy rating on shares of Gain Therapeutics (NASDAQ:GANX) in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has a $7.00 price target on the stock.

Other research analysts also recently issued research reports about the company. HC Wainwright reaffirmed a “buy” rating and set a $8.00 price target on shares of Gain Therapeutics in a research note on Monday, November 25th. Roth Capital raised shares of Gain Therapeutics to a “strong-buy” rating in a report on Thursday, December 5th. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $7.25.

Gain Therapeutics Price Performance

Shares of NASDAQ:GANX opened at $1.60 on Tuesday. The firm has a market capitalization of $42.44 million, a price-to-earnings ratio of -1.45 and a beta of 0.21. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.99 and a quick ratio of 2.99. The business’s 50 day simple moving average is $1.96 and its 200-day simple moving average is $1.60. Gain Therapeutics has a 12 month low of $0.89 and a 12 month high of $5.33.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Warberg Asset Management LLC acquired a new stake in shares of Gain Therapeutics during the 2nd quarter worth about $66,000. Renaissance Technologies LLC lifted its stake in shares of Gain Therapeutics by 154.2% during the second quarter. Renaissance Technologies LLC now owns 118,700 shares of the company’s stock valued at $152,000 after buying an additional 72,000 shares during the period. Geode Capital Management LLC boosted its position in Gain Therapeutics by 48.0% during the third quarter. Geode Capital Management LLC now owns 271,972 shares of the company’s stock worth $484,000 after acquiring an additional 88,236 shares during the last quarter. Finally, Hohimer Wealth Management LLC purchased a new stake in Gain Therapeutics in the 2nd quarter worth approximately $422,000. Institutional investors and hedge funds own 11.97% of the company’s stock.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.